Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including: Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin? Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma? What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome? What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last? Presenter: Noopur Raje, MD Professor of Medicine Harvard Medical School Director Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Boston, Massachusetts Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma. Link to full program: http://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.